TimesSquare Capital Management LLC boosted its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 491,250 shares of the biotechnology company’s stock after acquiring an additional 16,800 shares during the period. TimesSquare Capital Management LLC’s holdings in Sarepta Therapeutics were worth $27,333,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sarepta Therapeutics by 39.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 977 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 2,493 shares during the last quarter. Prentiss Smith & Co. Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter worth $199,000. Strs Ohio purchased a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth about $208,000. Finally, Brighton Jones LLC purchased a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth about $211,000. 84.79% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Inc (SRPT) opened at $74.36 on Friday. The company has a quick ratio of 9.52, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics Inc has a twelve month low of $28.14 and a twelve month high of $75.69.
Several equities research analysts have recently commented on the stock. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Monday, February 12th. Nomura raised their target price on shares of Sarepta Therapeutics to $96.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Oppenheimer reaffirmed a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. SunTrust Banks raised their target price on shares of Sarepta Therapeutics to $76.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $63.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have issued a buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus target price of $68.73.
COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics Inc (SRPT) Holdings Raised by TimesSquare Capital Management LLC” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2018/03/11/sarepta-therapeutics-inc-srpt-holdings-raised-by-timessquare-capital-management-llc.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.